Diagnostics News and Research

RSS

Thermo Fisher revenues increase 4% to $2.72 billion for first quarter 2011

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the first quarter ended April 2, 2011.

From Thermo Fisher Scientific Inc. 27 Apr 2011

Rwanda launches Africa's first nationwide cervical cancer vaccination, detection program

Rwandan First Lady Jeannette Kagame on Tuesday, in collaboration with two companies, launched a national cervical cancer vaccination and screening program, the first of its kind in Africa, the New Times reports.

27 Apr 2011

Biomagnetics accepts Los Alamos National Labs' optical biosensor for disease diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world's first integrated optical biosensor for disease diagnosis.

27 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Synthes, JNJ sign merger agreement for orthopaedics business

Johnson & Johnson, the world's most comprehensive and broadly-based manufacturer of health care products, and Synthes, Inc., a premier global manufacturer of orthopaedic devices, today announced that they have entered into a definitive agreement whereby Johnson & Johnson will acquire Synthes for CHF159 per share, or $21.3 billion.

27 Apr 2011

Magnetic 'nanobeads' help detect chemical and biological agents

Researchers at Oregon State University have found a way to use magnetic "nanobeads" to help detect chemical and biological agents, with possible applications in everything from bioterrorism to medical diagnostics, environmental monitoring or even water and food safety.

27 Apr 2011

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu. The diagnostic test, which runs on Cepheid's GeneXpert® System, simultaneously detects and differentiates Influenza A, Influenza B, and the 2009 H1N1 influenza virus in about one hour.

26 Apr 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

CSI's cancer cytogenetic testing receives COG approval

CSI Laboratories, a private national cancer diagnostics laboratory, has received approval from the Children's Oncology Group to begin analyzing pediatric cytogenetic cases. The Children's Oncology Group is the world's largest children's cancer research organization and includes more than 210 member hospitals with over 6,500 medical professionals.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

OCM announces acquisition of Diagnostics Plus

One Call Medical, the nation's leading provider of specialty services to insurance payers, today announced its acquisition of Diagnostics Plus, a provider network for advanced radiology and electrodiagnostic services, including MRIs, CT scans, and electromyography.

25 Apr 2011

Researchers to develop Alzheimer's diagnostic test based on spinal fluid biomarkers

Researchers at the University of Kentucky are working on a potential diagnostic test for Alzheimer's disease, based on biomarkers in cerebrospinal fluid.

25 Apr 2011

nSpire Health sales increase 3% to $27.6M for 2011

nSpire Health, LLC, a leading provider of respiratory diagnostic devices and clinical trial services, issued audited results for 2010 today. Sales of $27.6M are up 3% year over year. The Company reported a $3.6M improvement in EBIT when compared to 2009 and its highest profit since the founding of the company in 2006. Cash is up $2.4M and debt reduced to less than $400K.

25 Apr 2011

iMD to expand Medical Diagnostics operations

As a result of its recent acquisition announced yesterday of Optimum Mobile Imaging LLC ("OMI"), iMD is actively seeking to dramatically expand its overall Medical Diagnostics operations. Currently operating mainly in the Phoenix area, iMD will expand OMI's services throughout the state.

22 Apr 2011

Merrimack initiates dosing in MM-111 combination Phase 1 study in advanced HER2 positive patients

Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.

21 Apr 2011

Meridian Bioscience second quarter net sales increases 32% to $41.1 million

Meridian Bioscience, Inc., today reported fiscal 2011 second quarter and six months net sales of $41.1 million and $78.3 million, respectively, increases of 32% and 6%, respectively, from the same periods of the prior fiscal year;

21 Apr 2011

Biomagnetics signs agreement with LANL to develop validated TB biomarker assay

Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and related technology for detecting HIV, hepatitis, tuberculosis, cholera and malaria, and other innovative technologies, today announced it has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and development agreement (CRADA) executed in 2010 between the two organizations.

21 Apr 2011

RTCA HT instrument from Roche employs high-throughput real-time cell analysis

The new xCELLigence RTCA HT Instrument from Roche (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY) rounds out the Diagnostics Applied Science's portfolio in real-time cell analysis with a high-throughput product.

21 Apr 2011

U.S. DOD awards $4.5M to NYU Langone Medical Center for novel breast cancer research

NYU Langone Medical Center announced today the U.S. Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs has awarded Silvia Formenti, MD, the Sandra and Edward Meyer Professor and Chair of the Department of Radiation Oncology a $4.5 million Multi-Team Award to conduct novel breast cancer research.

21 Apr 2011

Intrinsic Bioprobes launches mass spectrometry-based protein assays for in-vitro diagnostic testing

Intrinsic Bioprobes Inc. ("IBI") today announced the launch of its first mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI's MASSAY® platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

20 Apr 2011